Has the U.K. Biotech Industry valuation changed over the past few years?

Investors are relatively neutral on the British Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PS ratio of 3.7x.

Which industries have driven the changes within the U.K. Healthcare industry?

There are no additional sub-industries under this industry.

U.K. (FTSE) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Tue, 21 Jul 2026	UK£3.2b	UK£895.1m	-UK£152,465,392.32	18.3x	-21x	3.6x
Thu, 18 Jun 2026	UK£3.3b	UK£893.6m	-UK£153,753,942.15	18.7x	-21.6x	3.7x
Sat, 16 May 2026	UK£3.1b	UK£892.4m	-UK£110,517,982.20	19.3x	-28x	3.5x
Mon, 13 Apr 2026	UK£3.2b	UK£893.1m	UK£2.6m	10.4x	1236.6x	3.5x
Wed, 11 Mar 2026	UK£3.3b	UK£875.5m	-UK£4,466,814.74	9.3x	-749.9x	3.8x
Fri, 06 Feb 2026	UK£3.8b	UK£876.1m	-UK£28,156,774.00	10.1x	-134x	4.3x
Sun, 04 Jan 2026	UK£3.3b	UK£896.7m	-UK£29,452,032.75	10.4x	-110.5x	3.6x
Tue, 02 Dec 2025	UK£3.2b	UK£895.2m	-UK£30,726,574.72	10.6x	-105.3x	3.6x
Thu, 30 Oct 2025	UK£3.3b	UK£886.4m	-UK£43,144,233.91	10.6x	-75.5x	3.7x
Sat, 27 Sep 2025	UK£3.2b	UK£879.8m	-UK£68,834,067.23	16.5x	-46.5x	3.6x
Mon, 25 Aug 2025	UK£3.4b	UK£854.5m	-UK£104,822,157.28	12.5x	-32.5x	4x
Wed, 23 Jul 2025	UK£2.9b	UK£854.4m	-UK£103,407,415.47	13.2x	-28.2x	3.4x
Fri, 20 Jun 2025	UK£2.5b	UK£857.4m	-UK£103,870,815.00	12.5x	-23.9x	2.9x
Sun, 18 May 2025	UK£2.4b	UK£879.6m	-UK£91,537,381.41	13.1x	-26.7x	2.8x
Tue, 15 Apr 2025	UK£2.1b	UK£876.6m	-UK£170,127,541.31	16.3x	-12.6x	2.4x
Thu, 13 Mar 2025	UK£2.3b	UK£844.0m	-UK£277,134,140.45	18.2x	-8.4x	2.8x
Sat, 08 Feb 2025	UK£2.7b	UK£842.2m	-UK£295,589,821.84	84x	-9.1x	3.2x
Mon, 06 Jan 2025	UK£2.6b	UK£842.1m	-UK£295,291,715.38	74.4x	-8.8x	3.1x
Wed, 04 Dec 2024	UK£2.8b	UK£840.5m	-UK£293,860,408.26	83.4x	-9.4x	3.3x
Fri, 01 Nov 2024	UK£2.9b	UK£840.4m	-UK£293,275,363.80	98.7x	-10x	3.5x
Sun, 29 Sep 2024	UK£2.9b	UK£839.6m	-UK£292,047,470.70	95.1x	-9.9x	3.4x
Tue, 27 Aug 2024	UK£2.6b	UK£836.4m	-UK£249,452,861.90	30.3x	-10.5x	3.1x
Thu, 25 Jul 2024	UK£2.6b	UK£837.9m	-UK£257,048,326.32	29.7x	-10.1x	3.1x
Sat, 22 Jun 2024	UK£2.6b	UK£835.8m	-UK£273,591,160.91	29.8x	-9.6x	3.1x
Mon, 20 May 2024	UK£3.0b	UK£836.8m	-UK£287,677,832.28	31.3x	-10.3x	3.5x
Wed, 17 Apr 2024	UK£3.1b	UK£902.9m	-UK£201,739,102.79	29.2x	-15.2x	3.4x
Fri, 15 Mar 2024	UK£3.1b	UK£897.6m	-UK£203,499,153.35	34.1x	-15.1x	3.4x
Sun, 11 Feb 2024	UK£3.4b	UK£913.4m	-UK£197,961,516.15	30.3x	-17x	3.7x
Tue, 09 Jan 2024	UK£6.4b	UK£1.3b	-UK£245,047,596.00	37.2x	-26.1x	5x
Thu, 07 Dec 2023	UK£6.2b	UK£1.3b	-UK£245,772,654.00	36.8x	-25.1x	4.9x
Sat, 04 Nov 2023	UK£6.4b	UK£1.3b	-UK£242,953,968.00	39.9x	-26.5x	5.1x
Mon, 02 Oct 2023	UK£6.5b	UK£1.3b	-UK£250,771,810.00	38x	-26.1x	5.1x
Wed, 30 Aug 2023	UK£6.6b	UK£1.3b	-UK£208,458,454.00	23.6x	-31.9x	5.3x
Fri, 28 Jul 2023	UK£6.9b	UK£1.3b	-UK£208,597,631.00	23.6x	-33.2x	5.5x


GB Market	0.26%
Healthcare	-1.81%
Biotech	0.23%
Biotech	0.23%

Company	Last Price	7D	1Y	Valuation
GNS Genus	UK£21.32	4.8% +UK£65.6m	-11.5%	PE30x
PRTC PureTech Health	UK£1.25	1.5% +UK£4.4m	-9.6%	PS87.7x
HEMO Hemogenyx Pharmaceuticals	UK£8.06	4.7% +UK£2.4m	453.0%	PB45.8x
SBTX SkinBioTherapeutics	UK£0.10	7.7% +UK£1.9m	-36.4%	PS5.2x
VAL ValiRx	UK£0.0016	13.8% +UK£153.6k	-72.5%	PS40.4x

Announcement • Jul 13

Faron Pharmaceuticals Oy Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab

Faron Pharmaceuticals Oy provided an update on its portfolio of Investigator-Initiated Trials (IITs) evaluating bexmarilimab, its wholly owned anti-Clever-1 immunotherapy, in multiple oncology indications. The update covers five IITs in solid tumors and hematological malignancies, reflecting both advances and adjustments across the program. The investigators of the BLAZE IIT, led by The Institute of Cancer Research (ICR) and conducted at The Royal Marsden NHS Foundation Trust in London, UK, as well as other UK hospitals, have updated the trial’s anti-PD-1 combination drug to nivolumab (Opdivo®), a fully approved, globally used standard-of-care anti-PD-1 inhibitor. The trial has received the necessary regulatory and ethical approvals and is advancing towards first patient enrolment. The BLAZE trial is a Phase 1/2 evaluating bexmarilimab in combination with nivolumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma who have developed resistance to prior anti-PD-1-based immunotherapy. The trial investigates a sequential approach: patients first receive a run-in dose of bexmarilimab to reprogram the immunosuppressive tumor microenvironment, followed by the combination of bexmarilimab and nivolumab, with the aim of resensitizing tumors to checkpoint inhibition. Using nivolumab as the combination backbone is scientifically meaningful, because its efficacy is well characterized. Therefore, clinical activity observed in the combination treatment can be better understood. The BEXAR trial has received the necessary regulatory and ethical approvals and is advancing towards first patient recruitment. BEXAR is a randomized Phase 1b/2 IIT sponsored by MEDSIR and conducted at six Spanish hospitals and led by Dr. Cesar Serrano at the University Hospital Vall d'Hebron in Barcelona, Spain. The trial evaluates bexmarilimab in combination with standard-of-care doxorubicin in patients with first-line metastatic soft-tissue sarcoma. The expression of bexmarilimab’s target, Clever-1, in soft-tissue sarcomas is among the highest observed across tumor types, providing a strong biological rationale for the use of bexmarilimab in this setting. Additionally, bexmarilimab's observed effects on hematopoiesis in the bone marrow may help offset the myelosuppressive effects of doxorubicin. The trial design includes exploratory endpoints to further evaluate this hypothesis in the sarcoma setting. The FINPROVE trial is an ongoing national, investigator-initiated precision medicine study sponsored by Helsinki University Hospital, designed to evaluate targeted treatment approaches across multiple tumor types. Following a regulatory review by the Finnish Medicines Agency (Fimea), the proposed bexmarilimab cohort was considered incompatible with the FINPROVE platform trial, which focuses primarily on marketed therapies with established and approved patient selection strategies. This outcome does not impact Faron’s broader development program for bexmarilimab. Two further IITs continue to advance through active protocol development and regulatory submission preparations. The BEAM-X trial, led by the Nordic AML Group, will evaluate bexmarilimab in patients with measurable residual disease-positive acute myeloid leukemia (AML) following allogeneic stem cell transplantation. In parallel, the IIT sponsored by City of Hope National Medical Center in the United States, is planned to evaluate bexmarilimab and orally administered decitabine-cedazuridine (Inqovi®) in relapsed or refractory myelodysplastic syndromes (r/r MDS). Further updates on both IITs will be provided in due course. Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

Announcement • Jun 16

Cizzle Biotechnology Holdings Plc CIZ1B Biomarker Test Approval For Clinical Use In USA

Cizzle Biotechnology Holdings Plc announced the successful laboratory accreditation of its proprietary test for the CIZ1B biomarker which is highly associated with early-stage lung cancer. Working closely with the Company's North American licensing partner Cizzle Bio Inc, the test is now approved for use under Clinical Laboratory Improvement Amendments accreditation at OmniHealth Diagnostics, a CLIA-certified, COLA-accredited clinical laboratory based in Dallas, Texas. CLIA approval is regulated by the Centers for Medicare & Medicaid Services and signifies that a laboratory's testing processes and assays meet US federal standards for timely clinical accuracy, reliability, and patient safety and will now enable the test to be made available to licensed U.S. healthcare providers. CLIA compliance is also mandatory for a laboratory to receive Medicare and Medicaid reimbursements. The CIZ1B biomarker test is a novel, ELISA-based immunoassay that detects a specific protein variant associated with early-stage lung cancer through a simple blood draw. The test is designed to complement LDCT screening and other standard-of-care diagnostic approaches, helping clinicians assess cancer risk, clarify indeterminate findings, and make more informed clinical decisions. Unlike multi-cancer early detection tests that rely on detecting circulating tumor DNA bearing mutation or methylation signals, CIZ1B is designed to detect a stable tumor-associated protein biomarker linked to lung cancer at its earliest stage. This distinct biomarker approach offers important advantages in identifying disease when intervention has the greatest potential to improve outcomes. CIZ1B is offered as a laboratory developed test and is performed exclusively within CLIA-certified laboratory environments, ensuring rigorous quality oversight, analytical control, and compliance with applicable regulatory standards. The validation at OmniHealth confirms the test's analytical performance and operational readiness within a U.S. clinical laboratory environment, supporting scalability, reproducibility, and integration into routine diagnostic workflows. This provides an accredited base to roll the test out across the USA and establishes a strong foundation for growth in other global and home markets. The CIZ1B biomarker test is built on foundational research into cancer origins, and the CIZ1 protein's role in epigenetic stability, led by Professor Dawn Coverley at the University of York. Her work led to the discovery of the CIZ1B protein variant and its strong association with lung cancer, and the development of molecular tools that can measure CIZ1B with high sensitivity in patients with early-stage lung cancer. With CLIA accreditation, clinicians and patients will now have access to a scalable test that can help with the detection of lung cancer in its early stages and improve a patient's chance of survival. Achieving CLIA accreditation is necessarily a complex and challenging task and was made possible through working closely with Cizzle's North American Licensing partner, BIO, and its clinical laboratory partner OmniHealth, bringing together the necessary research, development, regulatory, clinical and commercial expertise to deliver a vision to transform lung cancer survival through accurate, low cost, non-invasive early detection at scale. As part of the Company's global licensing strategy, there has been a first focus on the world's largest market in North America to launch its first commercial test. The goal is now to continue to work with the Company's partners to deliver early adoption and scale up. Having established a regulatory approved route to market in the USA, the Company is now also exploring new commercial relationships in the UK, elsewhere in Europe and Asia. This strategy aims to continue to deliver shareholder value through licensing-based royalty payments and potential benefits arising from equity participation in the partner companies where possible.

U.K. (FTSE) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Consensus EPS estimates fall by 27%

An asymmetric deep-value biotech incubator trapped in a severe conglomerate discount despite recurring proof of multi-billion dollar asset.

Faron Pharmaceuticals Oy Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab

Aptamer Group PLC Provides Earnings Guidance for the Fiscal Year 2026

Avacta Group plc Announces Appointment of Patrick Vink as Non-Executive Deputy Chairman and Senior Independent Director

GNS: Gene Editing Progress Will Drive Medium-Term Upside Potential

SkinBioTherapeutics plc Announces Termination of Emily Lorraine Bertram as Director, Effective June 30, 2026

Palatin Technologies, Inc., Annual General Meeting, Jul 28, 2026

ValiRx plc, Annual General Meeting, Jul 17, 2026

New minor risk - Financial data availability

Investor sentiment improves as stock rises 18%

Cizzle Biotechnology Holdings Plc CIZ1B Biomarker Test Approval For Clinical Use In USA

OptiBiotix Health Plc, Annual General Meeting, Jun 23, 2026

New minor risk - Share price stability